Allothera

Allothera is developing first-in-class small molecules that treat neuropathic pain at its source. Instead of suppressing symptoms through the central nervous system, Allothera targets the skin’s sensory interface — where pain signals begin. The company’s lead program focuses on STOML3, a key regulator of touch sensitiv

Allothera is a company in health.

Profile

Allothera is developing first-in-class small molecules that treat neuropathic pain at its source. Instead of suppressing symptoms through the central nervous system, Allothera targets the skin’s sensory interface — where pain signals begin. The company’s lead program focuses on STOML3, a key regulator of touch sensitivity, to prevent the abnormal conversion of touch into pain. […]

The company sits in the health segment, where it competes on its core product or service.

It is recorded at the Creative Destruction Lab alumni company stage.

Website: perceptatx.com